Skip to main content
EMV CAPITAL PLC logo

EMV CAPITAL PLC — Investor Relations & Filings

Ticker · EMVC ISIN · GB00BN4R5Q82 LEI · 213800N5WD46G1Y7I458 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2022-04-25 Regulatory Filings
Country GB United Kingdom
Listing IL EMVC

About EMV CAPITAL PLC

https://www.emvcapital.com/

EMV Capital PLC is a venture capital investment group specializing in deep tech and life sciences. The firm identifies, invests in, and builds high-growth, IP-rich companies with an international portfolio, focusing on sectors including industrial technology, healthcare, and sustainability. It employs a capital-efficient investment strategy that combines syndicated investments, direct balance sheet funding, and managed funds to support companies from their early stages through to successful exit. EMV Capital engages in proactive portfolio management, often taking board positions and working closely with company leadership. It provides extensive value creation services, including support for fundraising, exit readiness, IP strategy, and corporate collaborations, to drive growth and maximize returns for investors through strategic exits.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 100% confidence The document is a standard RNS (Regulatory News Service) notification from the London Stock Exchange regarding a 'Price Monitoring Extension' for NetScientific PLC. This is a technical market announcement related to trading parameters and does not fit into specific categories like financial reports, dividends, or management changes. Therefore, it falls under the fallback category for general regulatory announcements.
2022-04-25 English
PDS Provides Business Update & Full-Year Results
Earnings Release Classification · 95% confidence The document is an RNS (Regulatory News Service) announcement issued by NetScientific PLC regarding its portfolio company, PDS Biotechnology Corporation. It provides a summary of financial results and business updates for the year ended December 31, 2021. While it contains financial data, it is an initial announcement of results (Earnings Release) rather than the full audited Annual Report (10-K). The document also includes a link to the full announcement on the company's website, which is characteristic of an Earnings Release (ER) announcement. FY 2021
2022-03-31 English
Publication of Shareholder Newsletter
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) from NetScientific plc regarding the publication of a Shareholder Newsletter. It provides a link to the external document rather than containing the full content of the report itself. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2022-03-04 English
PDS Announces Preliminary Safety Data on PDS0101
Regulatory Filings Classification · 98% confidence The document is a press release issued by NetScientific PLC regarding clinical trial results from its portfolio company, PDS Biotechnology. It follows the standard format of an RNS (Regulatory News Service) announcement, providing a summary of preliminary safety data for a drug candidate. It does not constitute a full financial report, proxy statement, or annual report. As it is a general regulatory announcement regarding company news, it falls under the RNS category.
2022-02-24 English
PDS Clinical Trial with Mayo Clinic
Regulatory Filings Classification · 100% confidence The document is a press release issued via the London Stock Exchange's 'Reach' service, which is explicitly identified as a non-regulatory news distribution service. It announces the initiation of a clinical trial by a portfolio company (PDS Biotechnology) of NetScientific plc. Since it is a press release announcing corporate news rather than a formal financial report, and it fits the definition of a general regulatory/corporate announcement distributed via RNS, it is classified as RNS.
2022-02-15 English
PDS Phase 2 Trial Update
Regulatory Filings Classification · 95% confidence The document is a press release issued via the RNS (Regulatory News Service) Reach platform. It announces clinical trial results for a portfolio company (PDS Biotechnology) of NetScientific PLC. It is a standard corporate announcement regarding business operations and clinical progress, which falls under the 'Regulatory Filings' category as it is a general press release distributed through the London Stock Exchange's non-regulatory service.
2022-02-02 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.